Sara Cherradi

Grabels, France

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 13 publications

A new in vitro rat liver platform capturing biological diversity for drug-induced liver injury assessment and reduction of animal use in drug discovery and development.

A new in vitro rat liver platform capturing biological diversity for drug-induced liver injury assessment and reduction of animal use in drug discovery and development.

Journal: Frontiers in toxicology

Published: January 09, 2026

AI-enhanced clinical trial-in-a-dish platform for improved DILI risk classification and mechanistic insights into hepatotoxicity.

AI-enhanced clinical trial-in-a-dish platform for improved DILI risk classification and mechanistic insights into hepatotoxicity.

Journal: Frontiers in toxicology

Published: November 06, 2025

A serum-derived 3D tumor model platform for personalized prediction and monitoring of chemotherapeutic response in pancreatic ductal adenocarcinoma.

A serum-derived 3D tumor model platform for personalized prediction and monitoring of chemotherapeutic response in pancreatic ductal adenocarcinoma.

Journal: Translational oncology

Published: October 01, 2025

Modelling hepatocellular carcinoma microenvironment phenotype to evaluate drug efficacy.

Modelling hepatocellular carcinoma microenvironment phenotype to evaluate drug efficacy.

Journal: Scientific reports

Published: October 10, 2024

Uncovering the mechanism of troglitazone-mediated idiosyncratic drug-induced liver injury with individual-centric models.

Uncovering the mechanism of troglitazone-mediated idiosyncratic drug-induced liver injury with individual-centric models.

Journal: Archives of toxicology

Published: July 04, 2024

Exploiting the predictive power of educated spheroids to detect immune-mediated idiosyncratic drug-induced liver injury: the case of troglitazone.

Exploiting the predictive power of educated spheroids to detect immune-mediated idiosyncratic drug-induced liver injury: the case of troglitazone.

Journal: Frontiers in pharmacology

Published: January 29, 2024

An original donor-dependent spheroid system for the prediction of idiosyncratic drug-induced liver injury risk.

An original donor-dependent spheroid system for the prediction of idiosyncratic drug-induced liver injury risk.

Journal: In vitro models

Published: April 24, 2023

A monoclonal antibody targeting nonjunctional claudin-1 inhibits fibrosis in patient-derived models by modulating cell plasticity.

A monoclonal antibody targeting nonjunctional claudin-1 inhibits fibrosis in patient-derived models by modulating cell plasticity.

Journal: Science translational medicine

Published: December 21, 2022

Improving the response to oxaliplatin by targeting chemotherapy-induced CLDN1 in resistant metastatic colorectal cancer cells.

Improving the response to oxaliplatin by targeting chemotherapy-induced CLDN1 in resistant metastatic colorectal cancer cells.

Journal: Cell & bioscience

Published: November 08, 2022

Treatment of HCC with claudin-1-specific antibodies suppresses carcinogenic signaling and reprograms the tumor microenvironment.

Treatment of HCC with claudin-1-specific antibodies suppresses carcinogenic signaling and reprograms the tumor microenvironment.

Journal: Journal of hepatology

Published: February 21, 2022

Claudin gene expression profiles and clinical value in colorectal tumors classified according to their molecular subtype.

Claudin gene expression profiles and clinical value in colorectal tumors classified according to their molecular subtype.

Journal: Cancer management and research

Published: March 14, 2019

Antibody targeting of claudin-1 as a potential colorectal cancer therapy.

Antibody targeting of claudin-1 as a potential colorectal cancer therapy.

Journal: Journal of experimental & clinical cancer research : CR

Published: February 22, 2017

Showing 1-12 of 13

Last Updated: 09/26/2026